KURA
Price
$12.14
Change
+$0.15 (+1.25%)
Updated
Nov 28 closing price
Capitalization
1.06B
92 days until earnings call
Intraday BUY SELL Signals
STOK
Price
$30.91
Change
-$0.30 (-0.96%)
Updated
Nov 28 closing price
Capitalization
1.77B
101 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KURA vs STOK

Header iconKURA vs STOK Comparison
Open Charts KURA vs STOKBanner chart's image
Kura Oncology
Price$12.14
Change+$0.15 (+1.25%)
Volume$635.59K
Capitalization1.06B
Stoke Therapeutics
Price$30.91
Change-$0.30 (-0.96%)
Volume$318.77K
Capitalization1.77B
KURA vs STOK Comparison Chart in %
KURA
Daily Signal:
Gain/Loss:
STOK
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
KURA vs. STOK commentary
Dec 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KURA is a StrongBuy and STOK is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 01, 2025
Stock price -- (KURA: $12.14 vs. STOK: $30.91)
Brand notoriety: KURA and STOK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KURA: 31% vs. STOK: 25%
Market capitalization -- KURA: $1.06B vs. STOK: $1.77B
KURA [@Biotechnology] is valued at $1.06B. STOK’s [@Biotechnology] market capitalization is $1.77B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.02B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KURA’s FA Score shows that 1 FA rating(s) are green whileSTOK’s FA Score has 1 green FA rating(s).

  • KURA’s FA Score: 1 green, 4 red.
  • STOK’s FA Score: 1 green, 4 red.
According to our system of comparison, STOK is a better buy in the long-term than KURA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KURA’s TA Score shows that 4 TA indicator(s) are bullish while STOK’s TA Score has 7 bullish TA indicator(s).

  • KURA’s TA Score: 4 bullish, 4 bearish.
  • STOK’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, STOK is a better buy in the short-term than KURA.

Price Growth

KURA (@Biotechnology) experienced а +8.68% price change this week, while STOK (@Biotechnology) price change was +5.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.92%. For the same industry, the average monthly price growth was +1.16%, and the average quarterly price growth was +72.91%.

Reported Earning Dates

KURA is expected to report earnings on Mar 03, 2026.

STOK is expected to report earnings on Mar 11, 2026.

Industries' Descriptions

@Biotechnology (+6.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STOK($1.77B) has a higher market cap than KURA($1.06B). STOK YTD gains are higher at: 180.236 vs. KURA (39.380). STOK has higher annual earnings (EBITDA): 42.3M vs. KURA (-192.46M). KURA has more cash in the bank: 631M vs. STOK (248M). STOK has less debt than KURA: STOK (2.3M) vs KURA (19.5M). STOK has higher revenues than KURA: STOK (200M) vs KURA (83.3M).
KURASTOKKURA / STOK
Capitalization1.06B1.77B60%
EBITDA-192.46M42.3M-455%
Gain YTD39.380180.23622%
P/E RatioN/A45.46-
Revenue83.3M200M42%
Total Cash631M248M254%
Total Debt19.5M2.3M849%
FUNDAMENTALS RATINGS
KURA vs STOK: Fundamental Ratings
KURA
STOK
OUTLOOK RATING
1..100
5017
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
81
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9544
PRICE GROWTH RATING
1..100
3735
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KURA's Valuation (33) in the Biotechnology industry is somewhat better than the same rating for STOK (81) in the null industry. This means that KURA’s stock grew somewhat faster than STOK’s over the last 12 months.

KURA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as STOK (100) in the null industry. This means that KURA’s stock grew similarly to STOK’s over the last 12 months.

STOK's SMR Rating (44) in the null industry is somewhat better than the same rating for KURA (95) in the Biotechnology industry. This means that STOK’s stock grew somewhat faster than KURA’s over the last 12 months.

STOK's Price Growth Rating (35) in the null industry is in the same range as KURA (37) in the Biotechnology industry. This means that STOK’s stock grew similarly to KURA’s over the last 12 months.

STOK's P/E Growth Rating (4) in the null industry is significantly better than the same rating for KURA (100) in the Biotechnology industry. This means that STOK’s stock grew significantly faster than KURA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KURASTOK
RSI
ODDS (%)
Bearish Trend 3 days ago
80%
Bullish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
83%
Momentum
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 3 days ago
78%
MACD
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 7 days ago
86%
Declines
ODDS (%)
Bearish Trend 28 days ago
84%
Bearish Trend 11 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
KURA
Daily Signal:
Gain/Loss:
STOK
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
UINQX62.840.49
+0.79%
Victory Nasdaq 100 Index Institutional
ACMTX11.170.08
+0.72%
AB All Market Real Return C
TIHGX95.370.60
+0.63%
The Investment House Growth
QRLVX36.000.21
+0.59%
Federated Hermes MDT Large Cap Value R
LEQIX13.490.03
+0.22%
LoCorr Dynamic Opportunity I

STOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STOK has been loosely correlated with QTTB. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STOK
1D Price
Change %
STOK100%
-0.96%
QTTB - STOK
49%
Loosely correlated
+6.31%
DNLI - STOK
46%
Loosely correlated
+0.36%
SYRE - STOK
46%
Loosely correlated
+0.84%
NGNE - STOK
45%
Loosely correlated
+0.43%
KURA - STOK
45%
Loosely correlated
+1.25%
More